Menu
← Oncology Approval Tracker
FDA DECISION ·
Zynlonta
loncastuximab tesirine-lpyl · ADC Therapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory large B-cell lymphoma after two or more systemic treatment lines, including DLBCL, DLBCL arising from low-grade lymphoma and high-grade B-cell lymphoma.
LAMPGEN ANALYSIS
Why it matters
The CD19-directed antibody-drug conjugate adds a later-line approach for specified aggressive lymphomas.
What research teams should watch
Record the exact lymphoma subtype and prior line count and follow cytopenias and treatment interruptions.
PRIMARY RECORDS